[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577648":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Jinnah Postgraduate Medical Centre","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Erythrodermic Psoriasis",null,"Erythrodermic Psoriasis will be treated by injection Sekucinumab",[13],"Biological: injection Sekucinumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","injection Sekucinumab","All patients with erythrodermic psoriasis (EP), who will receive subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every 4 week. At weeks 0, 4, 8, 12, 16 and 20 the psoriasis area and severity index (PASI) will be recorded and adverse drug reactions, patient's satisfaction and recurrence will be observed.",[9],[21],{"name":22,"affiliation":23,"role":24},"Maria Iqbal, MBBS, FCPS Trainee","JPMC","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","00923001057555","mariashaikh140@gmail.com",[31],{"facility":32,"status":10,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Dermatology Jinnah Postgraduate Medical Center (JPMC), Karachi","Karachi","Sindh","22557","Pakistan","PK",{"type":39,"coordinates":40},"Point",[41,42],67.0104,24.8608,{"lat":42,"lon":41},[45],{"name":22,"role":27,"phone":46,"phoneExt":10,"email":29},"+923001057555",{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Maria Iqbal","Primary investigator, MBBS, FCPS Trainee","100577648","efficacy-of-injection-sekucinumab-in-erythrodermic-psoriasis-100577648",false,"NCT06801028","Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis","Inclusion criteria:\n\n* Patients of age 18-65 years age.\n* Either sex.\n* Patients presenting with the clinical manifestations of Erythrodermic Psoriasis such as redness, inflammation, skin rash, erythema, scaling, and itch on more than 90% of body surface area.\n\nExclusion criteria:\n\n* Patients of pediatric age.\n* Erythroderma caused by a condition other than psoriasis.\n* Patient treated with biologics for a different condition other than EP.\n* Diabetic, immunocompromised patients.\n* Women with pregnancy or lactating mothers.\n* Patients allergic to the drugs in this study.","ALL","18 Years","65 Years",{"count":60,"type":61},60,"ESTIMATED","OBSERVATIONAL","Erythroderma is a rare and severe dermatological manifestation of a variety of diseases. The most common form of erythroderma is erythrodermic psoriasis (EP), which accounts for 1-2.25% of all psoriatic patients, with a male predominance as demonstrated by a male to female ratio of 3:1. EP clinically manifests with diffuse erythema involving also skin folds with or without exfoliate dermatitis. Secukinumab is a FDA approved biological targeting interleukin-17A (IL17A) cytokine used in the treatment of moderate-to-severe psoriasis. Many clinical trials have been undertaken to establish its efficacy and safety in psoriasis. Numerous studies have highlighted the efficacy and safety of secukinumab. Secukinumab yields rapid and sustained improvements of signs and symptoms in patients EP. Secukinumab also had the lowest treatment cost compared with other biologic treatments for moderate to severe psoriasis. Secukinumab is a monoclonal antibody targeting IL-17, a key player in psoriasis pathogenesis, making it highly effective for psoriasis management. Erythrodermic psoriasis (EP) is a rare, severe form of the disease, affecting over 90% of the body, with significant health risks like electrolyte imbalance and infection. Treatment options for EP are not standardized due to its rarity, and conventional therapies such as acitretin, ciclosporin, and methotrexate have limited efficacy and tolerance issues. While biologics are well-studied for plaque psoriasis, data on EP is scarce. This study aims to evaluate secukinumab's efficacy in EP and explore factors influencing treatment outcomes.",[9],[9,66,67],"Efficacy","Sekucinumab","NOT_YET_RECRUITING","2025-01-23",{"date":71,"type":72},"2025-01-30","ACTUAL",{"date":74,"type":61},"2025-01-20",{"date":76,"type":61},"2025-05-30",{"name":5,"class":6},1]